Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.74 USD
Change Today -0.36 / -2.11%
Volume 864.2K
SPNC On Other Exchanges
As of 4:00 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

spectranetics corp (SPNC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/15 - $37.04
52 Week Low
07/24/15 - $15.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SPECTRANETICS CORP (SPNC)

Related News

No related news articles were found.

spectranetics corp (SPNC) Related Businessweek News

No Related Businessweek News Found

spectranetics corp (SPNC) Details

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; and coronary atherectomy and thrombectomy, which are aspiration for the treatment of blockages in the heart. Its primary crossing catheters include Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser mechanical sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It also offers the Stellarex DCB platform that is designed to treat peripheral arterial disease. The company sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.

753 Employees
Last Reported Date: 02/27/15
Founded in 1984

spectranetics corp (SPNC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $966.6K
Chief Financial Officer and Vice President
Total Annual Compensation: $506.4K
Chief Operating Officer
Total Annual Compensation: $448.5K
Senior Vice President and General Counsel
Total Annual Compensation: $392.0K
Senior Vice President of Sales & Marketing fo...
Total Annual Compensation: $390.0K
Compensation as of Fiscal Year 2014.

spectranetics corp (SPNC) Key Developments

The Spectranetics Corporation Enters into Third Amendment to Credit and Security Agreement

The Spectranetics Corporation announced that on June 26, 2015, the company entered into a Third Amendment to Credit and Security Agreement, by and between the company and Wells Fargo Bank, National Association, effective as of June 26, 2015. The Third Amendment amends the Credit and Security Agreement, dated February 25, 2011, between the company and Wells Fargo, as amended (together with the Third Amendment, the Credit and Security Agreement). Availability under the Credit and Security Agreement is subject to a borrowing base limitation of approximately $21 million as of May 31, 2015. The Third Amendment, among other things, (i) increases the availability under the Credit and Security Agreement from $15 million to $65 million and adds a $15 million uncommitted accordion feature, (ii) lowers the interest rate from 3-month LIBOR plus 2.75-3.25% (based on net income) to 3-month LIBOR plus 2.00-2.50% (based on liquidity), (iii) expands the borrowing base to include certain foreign accounts, equipment and real property, in addition to accounts receivable and inventory, (iv) as the sole financial covenant, requires that the Company maintain minimum liquidity of $25 million, and (v) relaxes several key covenants to provide greater flexibility for the Company to conduct its business. Except to the extent specifically amended by the Third Amendment, the Credit and Security Agreement remains in full force and effect. The company plans to draw $20 million on the line of credit on June 29, 2015. After giving effect to such borrowings, the company will have a total of $20 million in borrowings under the Credit and Security Agreement as of June 29, 2015.

The Spectranetics Reports Positive 12-Month Data from Clinical Trial of Laser Atherectomy Device

The Spectranetics reported promising 12-month data from the EXCITE ISR clinical trial. The company that results from the study show that Spectranetics' laser atherectomy devices used with PTA, are safer and more effective than PTA alone for treating femoropopliteal (FemPop) in-stent restenosis (ISR), demonstrating continued durability in 12-month results. Spectranetics said that the clinical results treating patients will set a new standard of care - one that will change clinical practice and will have lasting impact on physician protocols.

The Spectranetics Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM

The Spectranetics Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPNC:US $16.74 USD -0.36

SPNC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $15.54 USD +0.04
AtriCure Inc $27.93 USD +0.14
Cardiovascular Systems Inc $28.96 USD -0.88
Endologix Inc $14.06 USD -0.20
Vascular Solutions Inc $37.20 USD -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation SPNC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRANETICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at